JP2012525410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525410A5 JP2012525410A5 JP2012508648A JP2012508648A JP2012525410A5 JP 2012525410 A5 JP2012525410 A5 JP 2012525410A5 JP 2012508648 A JP2012508648 A JP 2012508648A JP 2012508648 A JP2012508648 A JP 2012508648A JP 2012525410 A5 JP2012525410 A5 JP 2012525410A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- combination
- virus
- mammal
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17341309P | 2009-04-28 | 2009-04-28 | |
| US61/173,413 | 2009-04-28 | ||
| PCT/US2010/032779 WO2010129339A2 (en) | 2009-04-28 | 2010-04-28 | Compositions and methods for enhancing antigen-specific immune responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014193613A Division JP2015017117A (ja) | 2009-04-28 | 2014-09-24 | 抗原特異的な免疫応答を高めるための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525410A JP2012525410A (ja) | 2012-10-22 |
| JP2012525410A5 true JP2012525410A5 (enExample) | 2013-06-20 |
| JP5690814B2 JP5690814B2 (ja) | 2015-03-25 |
Family
ID=43050757
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508648A Expired - Fee Related JP5690814B2 (ja) | 2009-04-28 | 2010-04-28 | 抗原特異的な免疫応答を高めるための組成物及び方法 |
| JP2014193613A Withdrawn JP2015017117A (ja) | 2009-04-28 | 2014-09-24 | 抗原特異的な免疫応答を高めるための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014193613A Withdrawn JP2015017117A (ja) | 2009-04-28 | 2014-09-24 | 抗原特異的な免疫応答を高めるための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120244173A1 (enExample) |
| EP (1) | EP2424990A4 (enExample) |
| JP (2) | JP5690814B2 (enExample) |
| AU (1) | AU2010246273B2 (enExample) |
| BR (1) | BRPI1011902A2 (enExample) |
| CA (1) | CA2760310A1 (enExample) |
| WO (1) | WO2010129339A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
| EP1644048B1 (en) | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
| CN104159607A (zh) * | 2012-01-24 | 2014-11-19 | 桑福德研究院/南达科他大学 | 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 |
| RU2019107976A (ru) | 2013-02-21 | 2019-08-23 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
| EP3013364B1 (en) * | 2013-06-25 | 2022-08-03 | International AIDS Vaccine Initiative, Inc. | Tuberculosis compositions and methods of using the same |
| WO2015106281A1 (en) * | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| WO2016025295A1 (en) * | 2014-08-06 | 2016-02-18 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| US10428122B2 (en) | 2016-06-16 | 2019-10-01 | International Aids Vaccine Initiative, Inc. | Tuberculosis compositions and methods of treating or preventing tuberculosis |
| US20210382037A1 (en) * | 2017-07-10 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents |
| CN113165866A (zh) * | 2018-10-04 | 2021-07-23 | Sqz生物技术公司 | 细胞内递送生物分子以增强抗原呈递细胞功能 |
| EP3897846A1 (en) * | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| US20230031287A1 (en) * | 2019-12-13 | 2023-02-02 | Northwestern University | Method and composition for enhancing the immune response |
| CN118302518A (zh) * | 2021-11-26 | 2024-07-05 | 汉阳大学校产学协力团 | 利用基因过表达建立能够有条件成熟的红系前体细胞系 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2038581A1 (en) * | 1990-03-20 | 1991-09-21 | Martin Muller | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
| AU2003249357A1 (en) * | 2002-06-27 | 2004-01-19 | Geron Corporation | Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase |
| EP1890724A2 (en) * | 2005-05-13 | 2008-02-27 | Oxxon Therapeutics Limited | Compositions for inducing an immune response |
| CA2634377A1 (en) * | 2005-12-21 | 2007-06-28 | Glaxo Group Limited | Method of eliciting immune response |
| EP2185193A1 (en) * | 2007-07-06 | 2010-05-19 | GENimmune N.V. | Methods for generating an immune response using dna and a viral vector |
-
2010
- 2010-04-28 WO PCT/US2010/032779 patent/WO2010129339A2/en not_active Ceased
- 2010-04-28 CA CA2760310A patent/CA2760310A1/en not_active Abandoned
- 2010-04-28 EP EP10772568.1A patent/EP2424990A4/en not_active Ceased
- 2010-04-28 US US13/318,028 patent/US20120244173A1/en not_active Abandoned
- 2010-04-28 JP JP2012508648A patent/JP5690814B2/ja not_active Expired - Fee Related
- 2010-04-28 AU AU2010246273A patent/AU2010246273B2/en not_active Ceased
- 2010-04-28 BR BRPI1011902A patent/BRPI1011902A2/pt not_active IP Right Cessation
-
2014
- 2014-09-24 JP JP2014193613A patent/JP2015017117A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12240873B2 (en) | Respiratory syncytial virus (RSV) vaccine | |
| US10925946B2 (en) | Vaccination methods | |
| EP2958994B1 (en) | Vaccine composition | |
| JP2019526580A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| JP2016128513A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| CN106459998A (zh) | 预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗 | |
| JP2013545448A5 (enExample) | ||
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| WO2014063601A1 (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| Mohebbi et al. | Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression | |
| CN114031675B (zh) | 基于SARS-CoV-2的S蛋白的疫苗和组合物 | |
| JP2023515806A5 (enExample) | ||
| JP2024534189A5 (enExample) | ||
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| Geng et al. | Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells | |
| EP3941513A1 (en) | Methods for inducing an immune response against neoantigens | |
| WO2002078732A1 (en) | A noval vaccine formulation consisting of dna vaccine inactivated virus | |
| CN102038951B (zh) | 基于mcp-1设计的核酸疫苗佐剂及其构建方法 | |
| Nosaka et al. | Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity | |
| JP7454320B2 (ja) | アジュバントとしての腫瘍溶解性ウイルス | |
| WO2019142933A1 (ja) | 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原 | |
| Yan et al. | COVID-19: The vaccine development strategies | |
| EP4514387A2 (en) | Method for enhancing immunity |